JEF vs XP

JEF presents a stark contrast between deep value and deteriorating operational health, highlighted by a weak Piotroski F-Score of 2/9. While the stock is significantly undervalued relative to its Graham Number ($58.99) and Intrinsic Value ($87.91), and trades below book value (P/B 0.93), the deterministic health metrics are alarming. Strong year-over-year revenue and earnings growth are offset by a bearish technical trend (0/100) and a recent negative Q/Q EPS growth of -27.1%. The investment case relies on a value-recovery thesis, but the operational red flags necessitate a cautious approach.

XP Inc. exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and financial stability. The stock is significantly undervalued, trading at $19.63, which is slightly below its Graham Number ($20.01) and far below its growth-based intrinsic value ($55.17). While the technical trend is currently bearish and insider sentiment is lukewarm, the combination of a low P/E (10.12), high ROE (23.71%), and consistent earnings growth makes it a compelling value play. The company's ability to maintain high profit margins (29.09%) while growing revenue by 13.3% YoY suggests a strong competitive moat in the capital markets sector.